Loading
Total declarations
Companies
▲ Purchases (22 ops.)
▼ Sales (12 ops.)
Latest filing published 20 May 2025 for Zomedica Corp., €20k.
Filing timeline
BuySaleJohnny D. Powers
Insider track record
Disclosed buys
22
Disclosed sells
12
T+90 hit rate
0%
T+90 mean return
-18.3%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Johnny D. Powers: trading record in brief
This profile gathers the share dealings of Johnny D. Powers across 3 companies, led by Idexx Laboratories INC /de, Zomedica Corp. and Zomedica Pharmaceuticals Corp. We count 87 filings; the first trade dates from 14 February 2010 and the latest from 19 May 2025.
Both buying and selling appear: 22 purchases worth €389k, against 12 sales worth €3.2M. The net balance comes to €2.8M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 13 share grants and 40 option exercises. 2025 to date brings 7 purchases and no sales.
Half of the purchases are above €9,764 and half below. Clusters matter here: 16 out of 20 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The latest filing, published on 20 May 2025, reports an open-market purchase of €20k in Zomedica Corp. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Johnny D. Powers
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
500,000 shares@ US$0.0464.4% of flowCommon Stock, without par valueSEC:0001654954-25-005943:0
Canonical exit: 17 Aug 2025 (T+90)
100,000 shares@ US$0.0691.3% of flowCommon Stock, without par valueSEC:0001654954-25-002963:0
Canonical exit: 15 Jun 2025 (T+90)
100,000 shares@ US$0.1212.4% of flowCommon Stock, without par valueSEC:0001654954-24-014107:0
Canonical exit: 9 Feb 2025 (T+90)
100,000 shares@ US$0.1292.5% of flowCommon Stock, without par valueSEC:0001654954-24-011206:0
Canonical exit: 26 Nov 2024 (T+90)
50,000 shares@ US$0.1791.7% of flowCommon Stock, without par valueSEC:0001654954-24-006605:0
Canonical exit: 15 Aug 2024 (T+90)
25,000 shares@ US$0.1840.9% of flowCommon Stock, without par valueSEC:0001654954-24-006580:0
Canonical exit: 14 Aug 2024 (T+90)
19,406 shares@ US$0.1390.5% of flowCommon Stock, without par valueSEC:0001654954-24-006413:0
Canonical exit: 12 Aug 2024 (T+90)
100,000 shares@ US$0.142.8% of flowCommon Stock, without par valueSEC:0001654954-24-006245:0
Canonical exit: 11 Aug 2024 (T+90)
100,000 shares@ US$0.1653.2% of flowCommon Stock, without par valueSEC:0001654954-23-015673:0
Canonical exit: 14 Mar 2024 (T+90)
100,000 shares@ US$0.1653.2% of flowCommon Stock, without par valueSEC:0001654954-23-015665:0
Canonical exit: 14 Mar 2024 (T+90)
100,000 shares@ US$0.1663.2% of flowCommon Stock, without par valueSEC:0001654954-23-014622:0
Canonical exit: 15 Feb 2024 (T+90)
150,000 shares@ US$0.1735.1% of flowCommon Stock, without par valueSEC:0001654954-23-014492:0
Canonical exit: 13 Feb 2024 (T+90)
100,000 shares@ US$0.19343.8% of flowCommon Stock, without par valueSEC:0001654954-23-007247:0
Canonical exit: 23 Aug 2023 (T+90)
250,000 shares@ US$0.4532.8% of flowCommon Stock, without par valueSEC:0001654954-21-012518:0
Canonical exit: 16 Feb 2022 (T+90)
125,000 shares@ US$0.268.9% of flowCommon Stock, without par valueSEC:0001171843-21-004365:0
125,000 shares@ US$0.268.4% of flowCommon Stock, without par valueSEC:0001171843-21-003571:0
16 of 16 declarations
